Icagen, Inc.
4222 Emperor Boulevard
Suite 350
Durham
North Carolina
27703
United States
Tel: 919-941-5206
Fax: 919-941-0813
Website: http://www.icagen.com/
Email: info@icagen.com
About Icagen, Inc.
Icagen, Inc. is a public biopharmaceutical company focused on the discovery, development and commercialization of novel, orally-administered, small-molecule drugs that modulate ion channel targets. Using our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates. Our two most advanced programs are:
We are also conducting ongoing drug discovery programs focused on new therapeutics for pain and inflammatory disorders. In each of these programs, we have identified small-molecule compounds that have demonstrated activity on specific ion channels. When we tested these compounds in preclinical studies, they showed desired activities and profiles, validating these ion channels as potential therapeutic targets for the particular indication. In addition to our internal programs, we have established a collaboration with Pfizer Inc focused on three sodium channel targets for the treatment of pain and related disorders. We plan to generate revenue from any product candidates that we successfully develop either through direct sales, collaboration arrangements with leading pharmaceutical and biotechnology companies, or a combination of these approaches.
For further information, see www.icagen.com.
Last Updated: 05-19-2008
177 articles about Icagen, Inc.
-
Icagen, Inc. Announces Presentation Related To Senicapoc At The 15th International Inflammation Research Association Conference
9/23/2008
-
Icagen, Inc. Reports Second Quarter 2008 Financial Results
8/5/2008
-
Icagen, Inc. to Report Second Quarter 2008 Results and Conduct Conference Call on August 5, 2008
7/29/2008
-
Icagen, Inc. Successfully Completes Phase I Multiple Ascending Dose Clinical Trial of Senicapoc
7/9/2008
-
Icagen, Inc. to Present At the Collins Stewart Fourth Annual Growth Conference On July 10, 2008
6/26/2008
-
Icagen, Inc. to Present At the Rodman & Renshaw 5th Annual Global Healthcare Conference On May 19, 2008
5/12/2008
-
Icagen, Inc. Reports First Quarter 2008 Financial Results
5/8/2008
-
Icagen, Inc. to Announce First Quarter 2008 Results and Conduct Conference Call On May 8, 2008
5/1/2008
-
Icagen, Inc. Announces Senior Management Promotions
3/20/2008
-
Icagen, Inc. and Pfizer Inc. Form Collaboration With Birkbeck, University of London to Elucidate Channel Structure
3/20/2008
-
Icagen, Inc. to Present At the Epilepsy Pipeline Conference On March 13, 2008
3/10/2008
-
Icagen, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3/5/2008
-
Icagen, Inc. to Announce Fourth Quarter and Full Year 2007 Results and Conduct Conference Call On March 5, 2008
2/27/2008
-
Icagen, Inc. to Present At BioBusiness 2008 On February 28, 2008
2/21/2008
-
Icagen, Inc. Announces Closing of Investment by Pfizer Inc.
2/15/2008
-
Icagen, Inc. Announces Second Investment By Pfizer Inc.
2/6/2008
-
Icagen, Inc. to Present At the 10th Annual Biotechnology Industry Organization (BIO) CEO and Investor Conference On February 12, 2008
2/5/2008
-
Icagen, Inc. Provides Update for Clinical Development of Senicapoc, a Novel Oral Small Molecule Ion Channel Blocker
1/8/2008
-
Icagen, Inc. to Present At the JPMorgan Healthcare Conference On January 10, 2008
1/3/2008
-
Icagen, Inc. Reports Third Quarter 2007 Financial Results
11/2/2007